Navigation Links
Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
Date:6/28/2010

e are two major types of diabetes: type 1 and type 2. Type 1, previously known as juvenile diabetes or insulin-dependent diabetes, is a disorder involving the body's immune system. In type 1 diabetes, the immune system attacks and destroys the insulin-producing beta cells in the pancreas. As a result of the decrease in endogenous (natural) insulin production, patients must monitor their glucose levels frequently and administer insulin regularly to control their blood glucose levels.

About Otelixizumab

Otelixizumab is a targeted T cell immunomodulator being developed for the treatment of type 1 diabetes and other autoimmune diseases. Otelixizumab targets CD3, a T lymphocyte receptor involved in normal cell signaling. Otelixizumab has not yet been approved for marketing. Data suggest that the antibody may work in patients with type 1 diabetes who have residual beta cells by blocking the function of effector T cells that mistakenly attack and destroy insulin-producing beta cells, while stimulating regulatory T cells that are understood to protect against effector T cell damage, thus preserving the beta cells' ability to make insulin.

About Tolerx

Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity. The company's pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline. TRX1, a Phase 1 candidate, is a nonlytic anti-CD4 antibody that is being developed for the treatment of aberrant or untoward immune responses.  The company also has three pre-clinical candidates, TRX518, TRX585 and TRX385, that enhance immune responses and as such are being evaluated fo
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
5. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
6. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
7. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
8. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 Based ... closure market, Frost & Sullivan recognises Incisive Surgical ... for Customer Value Leadership. Incisive Surgical,s uniquely-designed, innovative ... technology that eliminates the need for patients to ... and staple removal  that may result in increased ...
(Date:9/16/2014)... , Sept. 16, 2014 CorMedix ... focused on developing and commercializing therapeutic products for ... infectious diseases, announces the amendment and restatement of ... preferred stock and related warrants, as well as ... stock and warrant financing, to remove anti-dilution, price ...
(Date:9/16/2014)... , Sept. 16, 2014  DNAtrix, Inc., experts ... first patient was treated with the company,s lead ... interferon in a randomized, multicenter, open-label Phase Ib ... "DNAtrix, in collaboration with leading neurosurgeons and neuro-oncologists ... initiation of our randomized Phase Ib study of ...
Breaking Medicine Technology:Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 2Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 3Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 4Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 5CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2
... HARTLAND, Wis., Aug. 30, 2011 H&P Industries, Inc., ... hiring of Eamonn Vize to fill the Chief Operating ... 20 years of experience in the Pharmaceutical and Biotechnology ... provide his knowledge of Pharmaceutical Operations and Validations to ...
... , a leading supplier of embedded technologies, products, and ... embedded computers to a medical original equipment ... of the six-month contract is about 1.5M USD. ... will allow the customer to meet market demand and ...
Cached Medicine Technology:Eurotech Awarded 1.5M USD Contract to Supply Embedded Computers for Medical Application 2
(Date:9/16/2014)... McLean, Va. (PRWEB) September 16, 2014 ... use through predictive analytics and targeted clinical programs, ... The announced changes support the Company’s drive to ... analytics and targeted clinical programs. On September 2, ... parent company, Millennium Health, announced that RxAnte founder ...
(Date:9/16/2014)... News) -- Illegal drug use among teens in the United ... report. Encouragingly, the new study also found that ... among young people between the ages of 12 and 17 ... of 70,000 people aged 12 and older across the United ... abuse problems among this age group also dropped from 8.9 ...
(Date:9/16/2014)... YORK, NY (September 16, 2014) The Columbia ... the 2014 Higher Education Excellence in Diversity (HEED) ... and largest diversity-focused publication in higher education. As ... honor recognizing U.S. colleges and universities that demonstrate ... be featured along with 82 other recipients in ...
(Date:9/16/2014)... September 15, 2014A prospective study that compared patient-reported ... with bone metastases demonstrates that single fraction radiation ... fraction radiation therapy (MFRT) when pain, function and ... presented today at the American Society for Radiation ... indicates that improvements in patients, pain, function and ...
(Date:9/16/2014)... September 16, 2014 Fresh shiitake ... iron and potassium. They are second-most consumed mushroom ... and their healing and health properties. , In ... Shiitakes can stimulate and strengthen the immune system ... contain polycharrides, including beta glucans . These ...
Breaking Medicine News(10 mins):Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 3Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2Health News:Columbia University College of Dental Medicine receives diversity award 2Health News:Columbia University College of Dental Medicine receives diversity award 3Health News:Columbia University College of Dental Medicine receives diversity award 4Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 2Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 3
... ULURU Inc. (NYSE AMEX: ULU ) ... 31, 2009. The Company reported a net loss of $3.1 ... $1.8 million, or $0.03 per share, for the same period last ... cash equivalents of $5.1 million, compared with $7.6 million at December ...
... Calif., May 15 Thoratec Corporation (Nasdaq: ... support therapies to save, support and restore failing hearts, ... former chief operating officer of Boston Scientific, to its ... shareholders at the company,s annual shareholders, meeting on May ...
... Richard Boland, M.D., chief of gastroenterology at Baylor ... vice president of the American Gastroenterological Association (AGA) Institute, ... 2011. The oldest medical specialty society in the United ... and practice of gastroenterology. AGA membership includes 16,500 physicians ...
... & PARIS, FRANCE The International Union for ... Public Health Education (SOPHE) are pleased to release today ... standards and quality assurance systems of global capacity in ... Health Education & Behavior (Vol. 36, No. 3, ...
... of Ultrasound in Medicine is pleased to announce the ... All operators of ultrasound systems with an output display ... consists of 3 parts: Bioeffects and Biophysics, Prudent Use, ... the information from this 64 page publication, users can ...
... Group, Inc. (Nasdaq: NYER ) reported results for ... for third quarter of fiscal 2009 increased $1.3 million or ... the comparable quarter in the prior year. The increase ... new pharmacies over the past 12 months. Revenues slightly ...
Cached Medicine News:Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 2Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 3Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 4Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 5Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 6Health News:Thoratec Announces Appointment of Paul LaViolette to Board of Directors 2Health News:Thoratec Announces Appointment of Paul LaViolette to Board of Directors 3Health News:Dallas Gastroenterologist Named Vice President of Prestigious National Organization 2Health News:Special journal issues released on global health promotion and health education 2Health News:AIUM releases second edition of 'Medical Ultrasound Safety' 2Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 2Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 3Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 4Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 5
...
...
Rhoton Curettes, titanium, length 191 mm, straight....
Sundt Slim-Line Temporary Vessel Clips used for temporary vascular occlusion during intracranial surgical procedures. Non-magnetic, MP35N, MRI compatible, gold color. Bayonet....
Medicine Products: